Performance of BRCA1/ 2 mutation prediction models in male breast cancer patients
| Autor: | Carolien P. Schröder, E. W. Blom, Linda A.M. Janssen, Jwm Martens, Maaike P.G. Vreeswijk, W. A. G. van Zelst-Stams, C.H.M. van Deurzen, Muriel A. Adank, C. J. van Asperen, Rogier A. Oldenburg, Nizet H. Dijkstra, Setareh Moghadasi, Juul T. Wijnen, V. Grundeken, Margreet G. E. M. Ausems, Jan C. Oosterwijk, T. A. M. van Os, Mar Rodríguez-Girondo, Marielle W. G. Ruijs |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Proband medicine.medical_specialty Receiver operating characteristic business.industry medicine.disease Confidence interval 3. Good health 03 medical and health sciences Brca1 2 mutation 030104 developmental biology 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Male breast cancer Mutation (genetic algorithm) Genetics Medicine Family history skin and connective tissue diseases business Genetics (clinical) Predictive modelling |
| Zdroj: | Clinical Genetics. 93:52-59 |
| ISSN: | 0009-9163 |
| DOI: | 10.1111/cge.13065 |
| Popis: | To establish whether existing mutation prediction models can identify which male breast cancer (MBC) patients should be offered BRCA1 and BRCA2 diagnostic DNA screening, we compared the performance of BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm), BRCAPRO (BRCA probability) and the Myriad prevalence table ("Myriad"). These models were evaluated using the family data of 307 Dutch MBC probands tested for BRCA1/2, 58 (19%) of whom were carriers. We compared the numbers of observed vs predicted carriers and assessed the Area Under the Receiver Operating Characteristic (ROC) Curve (AUC) for each model. BOADICEA predicted the total number of BRCA1/2 mutation carriers quite accurately (observed/predicted ratio: 0.94). When a cut-off of 10% and 20% prior probability was used, BRCAPRO showed a non-significant better performance (observed/predicted ratio BOADICEA: 0.81, 95% confidence interval [CI]: [0.60-1.09] and 0.79, 95% CI: [0.57-1.09], vs. BRCAPRO: 1.02, 95% CI: [0.75-1.38] and 0.94, 95% CI: [0.68-1.31], respectively). Myriad underestimated the number of carriers in up to 69% of the cases. BRCAPRO showed a non-significant, higher AUC than BOADICEA (0.798 vs 0.776). Myriad showed a significantly lower AUC (0.671). BRCAPRO and BOADICEA can efficiently identify MBC patients as BRCA1/2 mutation carriers. Besides their general applicability, these tools will be of particular value in countries with limited healthcare resources. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text